BMS, Northwestern Team Up For Immuno-Oncology Studies
This article was originally published in Scrip
Executive Summary
Bristol-Myers Squibb will provide Opdivo (nivolumab), Yervoy (ipilimumab) and potentially other immuno-oncology (I-O) agents for Northwestern University cancer researchers and fund staff positions in the university's pharmaceutical testing labs under a partnership to evaluate therapies that harness the immune system to treat rare cancers.